Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 12.46
+0.47 (3.92%)
Jul 25, 2025, 3:00 PM CST
SHA:603567 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Net Income | 220.15 | 438.22 | 472.74 | 185.44 | 332.1 | 436.29 | Upgrade |
Depreciation & Amortization | 158.88 | 158.88 | 190.44 | 169 | 137.1 | 155.89 | Upgrade |
Other Amortization | 13.07 | 13.07 | 10.75 | 12.18 | 17.78 | 21.64 | Upgrade |
Loss (Gain) From Sale of Assets | 1.68 | 1.68 | 0.26 | -39.52 | 0.89 | 0.11 | Upgrade |
Asset Writedown & Restructuring Costs | 0.63 | 0.63 | 3.91 | 1.47 | 0.3 | 0.11 | Upgrade |
Loss (Gain) From Sale of Investments | 9.69 | 9.69 | -464.47 | -24.73 | -242.67 | -20.32 | Upgrade |
Provision & Write-off of Bad Debts | 117.82 | 117.82 | 3.84 | -29.8 | 44.34 | 35.38 | Upgrade |
Other Operating Activities | 246.62 | 191.94 | 233.95 | 162.63 | 211.71 | 155.78 | Upgrade |
Change in Accounts Receivable | 304.34 | 304.34 | -891.41 | 107.18 | -1,233 | -548.8 | Upgrade |
Change in Inventory | -850.83 | -850.83 | 282.66 | -270.89 | 381.02 | -217.01 | Upgrade |
Change in Accounts Payable | -214.5 | -214.5 | -277.49 | -521.86 | -74.84 | 170.89 | Upgrade |
Change in Other Net Operating Assets | - | - | - | 0.62 | -0.87 | - | Upgrade |
Operating Cash Flow | 0.91 | 164.31 | -478.24 | -326.79 | -433.94 | 155.18 | Upgrade |
Operating Cash Flow Growth | - | - | - | - | - | -29.76% | Upgrade |
Capital Expenditures | -211.14 | -189.15 | -95.14 | -404.27 | -448.63 | -868.65 | Upgrade |
Sale of Property, Plant & Equipment | 118.15 | 118.2 | 129.45 | 0.64 | 3.7 | 0.87 | Upgrade |
Cash Acquisitions | - | - | - | -17.51 | - | - | Upgrade |
Divestitures | 0 | 0 | 94.87 | 369.74 | 373 | 50 | Upgrade |
Investment in Securities | -35.86 | -48.86 | -53 | 222.9 | -757.24 | -636.85 | Upgrade |
Other Investing Activities | 13.79 | 13.79 | 100.25 | 112.44 | 407.91 | 3.74 | Upgrade |
Investing Cash Flow | -115.07 | -106.02 | 176.43 | 283.93 | -421.26 | -1,451 | Upgrade |
Long-Term Debt Issued | - | 1,790 | 2,655 | 1,680 | 860 | 2,140 | Upgrade |
Total Debt Issued | 2,040 | 1,790 | 2,655 | 1,680 | 860 | 2,140 | Upgrade |
Long-Term Debt Repaid | - | -1,880 | -2,441 | -1,724 | -1,138 | -1,618 | Upgrade |
Total Debt Repaid | -2,335 | -1,880 | -2,441 | -1,724 | -1,138 | -1,618 | Upgrade |
Net Debt Issued (Repaid) | -295.19 | -90.19 | 214.05 | -44.4 | -278.12 | 522.11 | Upgrade |
Issuance of Common Stock | - | - | 219.68 | - | 1,228 | 101 | Upgrade |
Repurchase of Common Stock | - | - | - | -29.99 | - | - | Upgrade |
Common Dividends Paid | -183.47 | -324.28 | -158.28 | -243.55 | -143.73 | -332.22 | Upgrade |
Other Financing Activities | 5.81 | -39.7 | 490.24 | -101 | -8.7 | 1.21 | Upgrade |
Financing Cash Flow | -472.84 | -454.16 | 765.69 | -418.94 | 797.46 | 292.11 | Upgrade |
Net Cash Flow | -587 | -395.88 | 463.87 | -461.81 | -57.74 | -1,004 | Upgrade |
Free Cash Flow | -210.23 | -24.84 | -573.38 | -731.07 | -882.57 | -713.47 | Upgrade |
Free Cash Flow Margin | -10.23% | -0.92% | -18.27% | -17.35% | -21.39% | -20.96% | Upgrade |
Free Cash Flow Per Share | -0.22 | -0.03 | -0.61 | -0.78 | -1.02 | -0.84 | Upgrade |
Cash Income Tax Paid | 287.36 | 316.2 | 380.65 | 201.36 | 429.61 | 436.47 | Upgrade |
Levered Free Cash Flow | -505.86 | -272.95 | -746.75 | -404.69 | -881.7 | -1,337 | Upgrade |
Unlevered Free Cash Flow | -421.23 | -187.27 | -662.12 | -318.01 | -791.21 | -1,244 | Upgrade |
Change in Net Working Capital | 580.14 | 547.74 | 886.34 | -40.53 | 666.44 | 918.44 | Upgrade |
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.